tbuckley/cabot-search huggingface dataset:
Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma
Authors: Jun Du, Dandan Yu, Xinle Han, Lijun Zhu, Zoufang Huang
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Hematopoietic stem cell transplant (HSCT) is an advisable option for refractory or relapsed peripheral T-cell lymphoma (R/R-PTCL), but whether allogeneic HSCT or autologous HSCT is more beneficial is unknown. <h3>Objective</h3> To compare the effectiveness and safety of allogeneic HSCT vs autologous HSCT in patients with R/R-PTCL. <h3>Data Sources</h3> A systematic search of the PubMed, Embase, the Cochrane Central Register of Controlled Trials, Wanfang, and China National Knowledge Infrastructure databases with the search items<i>refractory or relapsed peripheral T-cell lymphoma</i>,<i>ASCT/autologous stem-cell transplantation</i>,<i>allo-HSCT/allogeneic stem-cell transplantation</i>,<i>therapeutic effect</i>, and<i>treatment</i>was conducted for articles published from January 12, 2001, to October 1, 2020. <h3>Study Selection</h3> After duplicate and irrelevant publications were discarded, 329 were ineligible according to the inclusion (clinical trials or retrospective studies with &gt;10 samples) and exclusion criteria (articles without overall survival [OS], progression-free survival [PFS], and transplantation-related mortality [TRM]). Thirty trials were included in the meta-analysis. The study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. <h3>Data Extraction and Synthesis</h3> Data on study design, individual characteristics, and outcomes were extracted. All statistics were pooled by applying a random-effects model. <h3>Main Outcomes and Measures</h3> The prespecified main outcomes were OS, PFS, and TRM. <h3>Results</h3> Of 6548 articles, data extracted from the 30 studies (including 880 patients who underwent allogeneic HSCT and 885 who underwent autologous HSCT) were included in this meta-analysis. In the allogeneic HSCT group, a 3-year OS of 50% (95% CI, 41%-60%) and PFS of 42% (95% CI, 35%-51%), a 5-year OS of 54% (95% CI, 47%-62%) and PFS of 48% (95% CI, 40%-56%), and a 3-year TRM of 32% (95% CI, 27%-37%) were observed. In the autologous HSCT group, a 3-year OS of 55% (95% CI, 48%-64%) and PFS of 41% (95% CI, 33%-51%), a 5-year OS of 53% (95% CI, 44%-64%) and PFS of 40% (95% CI, 24%-58%), and a 3-year TRM of 7% (95% CI, 2%-23%) were observed. <h3>Conclusions and Relevance</h3> In this systematic review and meta-analysis, OS and PFS were similar in the allogeneic HSCT and autologous HSCT groups; however, allogeneic HSCT was associated with specific survival benefits among patients with R/R-PTCL.
Recommendations for Statistical Reporting in Cardiovascular Medicine: A Special Report From the American Heart Association
Authors: Andrew D. Althouse, Jennifer E. Below, Brian L. Claggett, Nancy J. Cox, James A. de Lemos, Rahul C. Deo, Sue Duval, Rory Hachamovitch, Sanjay Kaul, Scott W. Keith, Eric Secemsky, Armando Teixeira-Pinto, Veronique L. Roger
Journal: Circulation (2021)

Statistical analyses are a crucial component of the biomedical research process and are necessary to draw inferences from biomedical research data. The application of sound statistical methodology is a prerequisite for publication in the American Heart Association (AHA) journal portfolio. The objective of this document is to summarize key aspects of statistical reporting that might be most relevant to the authors, reviewers, and readership of AHA journals. The AHA Scientific Publication Committee convened a task force to inventory existing statistical standards for publication in biomedical journals and to identify approaches suitable for the AHA journal portfolio. The experts on the task force were selected by the AHA Scientific Publication Committee, who identified 12 key topics that serve as the section headers for this document. For each topic, the members of the writing group identified relevant references and evaluated them as a resource to make the standards summarized herein. Each section was independently reviewed by an expert reviewer who was not part of the task force. Expert reviewers were also permitted to comment on other sections if they chose. Differences of opinion were adjudicated by consensus. The standards presented in this report are intended to serve as a guide for high-quality reporting of statistical analyses methods and results.
A Randomized Clinical Trial on Anterior Approach vs Conventional Hepatectomy for Resection of Colorectal Liver Metastasis—To Terminate or Not to Terminate the Study
Authors: Divya Gupta, J. Jack Lee, Albert Y. Lin
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
Engineering digital biomarkers of interstitial glucose from noninvasive smartwatches
Authors: Brinnae Bent, Peter J. Cho, Maria Henriquez, April Wittmann, Connie Thacker, Mark Feinglos, Matthew J. Crowley, Jessilyn P. Dunn
Journal: npj Digital Medicine (2021)

Abstract Prediabetes affects one in three people and has a 10% annual conversion rate to type 2 diabetes without lifestyle or medical interventions. Management of glycemic health is essential to prevent progression to type 2 diabetes. However, there is currently no commercially-available and noninvasive method for monitoring glycemic health to aid in self-management of prediabetes. There is a critical need for innovative, practical strategies to improve monitoring and management of glycemic health. In this study, using a dataset of 25,000 simultaneous interstitial glucose and noninvasive wearable smartwatch measurements, we demonstrated the feasibility of using noninvasive and widely accessible methods, including smartwatches and food logs recorded over 10 days, to continuously detect personalized glucose deviations and to predict the exact interstitial glucose value in real time with up to 84% and 87% accuracy, respectively. We also establish methods for designing variables using data-driven and domain-driven methods from noninvasive wearables toward interstitial glucose prediction.
Projecting the Incidence of Type 2 Diabetes–Related End-Stage Kidney Disease Until 2040: A Comparison Between the Effects of Diabetes Prevention and the Effects of Diabetes Treatment
Authors: Jedidiah I. Morton, Stephen P. McDonald, Agus Salim, Danny Liew, Jonathan E. Shaw, Dianna J. Magliano
Journal: Diabetes Care (2021)

OBJECTIVE This study sought to examine the effects of two diabetes prevention approaches and of widespread use of sodium–glucose cotransporter 2 inhibitors (SGLT2is) among people with diabetes on the future incidence of diabetes-related end-stage kidney disease (ESKD-D). RESEARCH DESIGN AND METHODS We developed a life table model to project the incidence of ESKD-D for type 2 diabetes in Australia until 2040. We projected incident ESKD-D under three separate scenarios: a large-scale lifestyle modification program for diabetes prevention; a population-wide sugar-sweetened beverage tax for diabetes prevention; and widespread use of SGLT2is among people with diabetes. RESULTS Assuming current trends, we projected that the annual incidence of ESKD-D will increase from 3.7 per 100,000 of the general population in 2014 to 5.7 by 2040. Incorporating the diabetes prevention approaches, we projected that the annual incidence of ESKD-D will be between 5.2 and 5.5 per 100,000 by 2040. When we modeled scenarios in which 50% and 70% of eligible people with diabetes were prescribed an SGLT2i, the annual incidence of ESKD-D by 2040 was projected to be 4.7 and 4.3 per 100,000, respectively. SGLT2is were projected to reduce the total number of incident ESKD-D cases between 2020 and 2040 by 12–21% compared with current trends, whereas diabetes prevention reduced cases by 1–3%. CONCLUSIONS It is likely that the number of people developing ESKD-D will increase over the coming decades, although widespread SGLT2i use will be effective at limiting this increase. Diabetes prevention will be crucial to prevent an ever-increasing burden of diabetes complications.
Moving from bytes to bedside: a systematic review on the use of artificial intelligence in the intensive care unit
Authors: Davy van de Sande, Michel E. van Genderen, Joost Huiskens, Diederik Gommers, Jasper van Bommel
Journal: Intensive Care Medicine (2021)

Due to the increasing demand for intensive care unit (ICU) treatment, and to improve quality and efficiency of care, there is a need for adequate and efficient clinical decision-making. The advancement of artificial intelligence (AI) technologies has resulted in the development of prediction models, which might aid clinical decision-making. This systematic review seeks to give a contemporary overview of the current maturity of AI in the ICU, the research methods behind these studies, and the risk of bias in these studies. A systematic search was conducted in Embase, Medline, Web of Science Core Collection and Cochrane Central Register of Controlled Trials databases to identify eligible studies. Studies using AI to analyze ICU data were considered eligible. Specifically, the study design, study aim, dataset size, level of validation, level of readiness, and the outcomes of clinical trials were extracted. Risk of bias in individual studies was evaluated by the Prediction model Risk Of Bias ASsessment Tool (PROBAST). Out of 6455 studies identified through literature search, 494 were included. The most common study design was retrospective [476 studies (96.4% of all studies)] followed by prospective observational [8 (1.6%)] and clinical [10 (2%)] trials. 378 (80.9%) retrospective studies were classified as high risk of bias. No studies were identified that reported on the outcome evaluation of an AI model integrated in routine clinical practice. The vast majority of developed ICU-AI models remain within the testing and prototyping environment; only a handful were actually evaluated in clinical practice. A uniform and structured approach can support the development, safe delivery, and implementation of AI to determine clinical benefit in the ICU.
OP0305 VALIDATION OF THE PSORIASIS EPIDEMIOLOGY SCREENING TOOL (PEST) AND THE NEW EARLY ARTHRITIS FOR PSORIATIC PATIENTS (EARP) IN PEDIATRIC POPULATION - PILOT STUDY
Authors: Y. Butbul
Journal: Annals of the Rheumatic Diseases (2021)

Background: Juvenile Psoriatic Arthritis (JPsA) is an inflammatory arthritis associated with irreversible joint damage among the pediatric population, which is associated with psoriasis in most cases. While there are few validated screening tools for diagnosis of arthritis for adult patients with psoriasis, those screening tools were never evaluated in children. Objectives: The aims of this study were to evaluate two screening tools among pediatric patients with psoriasis. Methods: Thirty-nine patients with the diagnosis of psoriasis were administered two screening questionnaires: the new Early Arthritis for Psoriatic Patients (EARP) questionnaire and the Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire. All patients were evaluated by a rheumatologist for the diagnosis of JPsA, and the accuracy of the two questionnaires compared. Results: The 4/39 (10.1%) patients diagnosed with JPsA had a PEST questionnaire score of ≥ 3, compared to a median PEST score of the patients without the diagnosis of JPsA of 0 (0-2). Thus both the sensitivity and specificity of the PEST in diagnosing JPsA were 100%. For the EARP questionnaire, 8/39 patients had a screening questionnaire score of ≥ 3, suggestive of JPsA, four were true positive, and four false positive. Thus, the sensitivity and specificity of EARP in diagnosing JPsA were 100% and 89%, respectively. Conclusion: Both the PEST and EARP questionnaires were easy to use and had high sensitivity for pediatric population with psoriasis, however the PEST questionnaire had a higher specificity than the EARP. Disclosure of Interests: None declared.
SARS-COV-2 vaccination after stem cell transplantation for scleroderma
Authors: Doron Rimar, Gleb slobodin, Alona Paz, Israel Henig, Tsila Zuckerman
Journal: Annals of the Rheumatic Diseases (2021)

Autologous haematological stem cell transplantation (AHSCT) for rapidly progressive severe systemic sclerosis (SSc) is the only treatment, so far, allowing long-term improvement in overall and event-free survival.1 2 The COVID-19 pandemic has challenged experts regarding decisions on AHSCT in these high-risk patients.3 Increased risk for severe COVID-19 infection in SSc is related to lung and heart involvement4 and is enhanced by high-dose immunosuppressive drugs and antithymocyte globulins used for conditioning to eliminate autoreactive cells before AHSCT and to allow reset of tolerance during the immune reconstitution period, lasting around 12 months after transplant.1 3 Several centres have stopped AHSCT activity for SSc during the pandemic for safety considerations. Others decided to continue, believing that the benefit of AHSCT is greater than the …
Too early to aʼMUSE!
Authors: Sanjay Chandnani, Ravi Thanage, Qais Contractor, Pravin Rathi
Journal: Endoscopy (2021)

See also: Transoral incisionless fundoplication with an ultrasonic surgical endostapler for the treatment of gastroesophageal reflux disease: 12-month outcomesEndoscopy 2020; 52(06): 469-473DOI: 10.1055/a-1124-3187 See also: Reply to Chandnani et al.Endoscopy 2021; 53(06): 665-665DOI: 10.1055/a-1345-8648
The challenges and opportunities of mental health data sharing in the UK
Authors: Tamsin Ford, Karen L Mansfield, Sarah Markham, Sally McManus, Ann John, Dermot O'Reilly, Tamsin Newlove-Delgado, Matthew H Iveson, Mina Fazel, Jayati Das Munshi, Rina Dutta, Gerard Leavy, Johnny Downs, Tom Foley, Abigail Russell, Aideen Maguire, Graham Moon, Elizabeth J Kirkham, Katie Finning, Ginny Russell, Anna Moore, Peter B Jones, Sarah Shenow
Journal: The Lancet Digital Health (2021)
Coronary artery disease patients without standard modifiable risk factors (SMuRFs)- a forgotten group calling out for new discoveries
Authors: Gemma A Figtree, Stephen T Vernon
Journal: Cardiovascular Research (2021)

We are interventional cardiologists working in a "whole of pipeline" research program based at the University of Sydney and Royal North Shore Hospital, driven by the increasing number of heart attack patients who look up from the cath-lab table asking "why me?".Coronary heart disease kills 7.2 million people per year, 1 many of whom were unaware of their underlying coronary atherosclerosis until their heart attack.While it is imperative that we target well-established risk factors, this approach "misses" a substantial group of patients who develop disease despite not being identified as "at risk" by traditional measures and cannot benefit from effective primary prevention measures.We are working with a growing international movement recognising the importance of this group of patients who suffer life-threatening heart attacks despite having no standard modifiable risk factors (SMuRFs) (Figure 1).We have coined the term "SMuRFless" for these individuals, and shown in Australia that the proportion of heart attack patients in this category has significantly increased over 10 years 2 from 13% to 27%. 3 Whilst this is a relatively small proportion of the "pie", the vast burden of CAD means these individuals cannot afford to be ignored, estimated to affect, conservatively, 29.6 million people globally, and to account for 1.4 million deaths per year. 7Most often overlooked in clinical trials and guidelines, we recognised the importance of understanding the outcomes for these SMuRFless individuals, and established a fabulous collaboration with the SWEDEHEART team, including Emil Hagstrom, Nermin Hadziosmanovic and Johan Sundstro ¨m.Meeting weekly throughout COVID times, we were able to benefit from the massive and well curated SWEDEHEART national registry, 4,5 which enrols all patients admitted to cardiac care units in Sweden with myocardial infarction.The findings, in 62,048 ST elevation MI patients were stunning and completely unexpected: STEMI patients with no SMuRFs experienced a 47% higher 30-day mortality compared to their counterparts with >0 SMuRFs.This compounded the already recognised poor outcomes in females, with SMuRFless females having an 18% 30-day mortality.
OP0107 CLINICAL EFFICACY OF ROMOSOZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS FOR 12 MONTHS
Authors: Y. Kanayama, R. Sugimoto
Journal: Annals of the Rheumatic Diseases (2021)

Background: Romosozumab (ROMO), a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption. And although it is a novel therapeutic agent for osteoporosis, which has shown high effects of increasing bone density and inhibiting fragile fracture in overseas clinical trials. However the clinical efficacy for rheumatoid arthritis complicated with osteoporosis (RA-OP) is unknown. Objectives: To evaluate the clinical efficacy of ROMO in patients with RA-OP for 12 months. Methods: RA patients diagnosed according to the 2010 ACR/EULAR criteria. All patients met at least one of the following criteria were eligible; a bone mineral density T score of -2.5 or less at the lumber spine or total hip and either one or more moderate or severe vertebral fractures or two or more mild vertebral fractures. All patients were initiated ROMO from between March and December, 2019. The total number of patients was 13 cases. The ROMO dose was 210mg at once every 1 months. In all cases native or activated vitamin D has been used. We reviewed the results for 12 months about the increase and decrease of bone mineral density (BMD) of lumbar spine(LS) and total hip(TH) by DEXA and bone turnover markers, intact n-terminal propeptide type I procollagen(PINP) and tartrate-resistant acid phopshatate form 5b(TRACP-5b). Results: The gender was all female. The mean age was 73.2 ± 7.6; disease duration was 20.5 ± 16.9 years; the body mass index was 19.7 ± 3.0 and the FRAX was 40.5 ± 16.2. Clinical findings related to RA-OP at baseline were as follows; CRP 1.29 ± 1.66; DAS-CRP 3.43 ± 0.96; HAQ 1.59 ± 0.97 and, bone turnover markers and bone mineral density at baseline were as follows; P1NP 58.1 ± 33.5; TRACP-5b 438 ± 216; LS-BMD and T-score 0.81 ± 0.15 g/cm 2 and -2.63 ± 1.05 and TH-BMD 0.54 ± 0.08 g/cm 2 and -3.22 ± 0.64 g/cm 2 . The rate of increased P1NP from baseline to 1, 3, 6 and 12 months were each 114.3 ± 90.6% at 1 month, 131.6 ± 134.3% at 3 month, 122.6 ± 174.3% at 6 month and 80.4 ± 181.6% at 12 month and decreased TRAC-5b were -10.7 ± 20.8% at 1 month, 7.9 ± 36.9% at 3 month, 25.5 ± 64.6% at 6 month and 32.5 ± 77.0% at 12 month. The rate of increased LS-BMD from baseline to 6 and 12 months were 8.6 ± 8.0%, 12.5 ± 11.1% and TH-BMD were 4.3 ± 5.0%, 6.8 ± 6.9% (Fig. 1, 2). Conclusion: Clinical efficacy of ROMO for RA-OP was extremely effective and has the high potential to be an important option in the treatment of RA-OP. References: Disclosure of Interests: None declared
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
Authors: Victoria Furer, Tali Eviatar, Devy Zisman, Hagit Peleg, Daphna Paran, David Levartovsky, Michael Zisapel, Ofir Elalouf, Ilana Kaufman, Roni Meidan, Adi Broyde, Ari Polachek, Jonathan Wollman, Ira Litinsky, Katya Meridor, Hila Nochomovitz, Adi Silberman, Dana Rosenberg, Joy Feld, Amir Haddad, Tal Gazzit, Muna Elias, Nizar Higazi, Fadi Kharouf, Gabi Shefer, Orly Sharon, Sara Pel, Sharon Nevo, Ori Elkayam
Journal: Annals of the Rheumatic Diseases (2021)

Introduction Vaccination represents a cornerstone in mastering the COVID-19 pandemic. Data on immunogenicity and safety of messenger RNA (mRNA) vaccines in patients with autoimmune inflammatory rheumatic diseases (AIIRD) are limited. Methods A multicentre observational study evaluated the immunogenicity and safety of the two-dose regimen BNT162b2 mRNA vaccine in adult patients with AIIRD (n=686) compared with the general population (n=121). Serum IgG antibody levels against SARS-CoV-2 spike S1/S2 proteins were measured 2–6 weeks after the second vaccine dose. Seropositivity was defined as IgG ≥15 binding antibody units (BAU)/mL. Vaccination efficacy, safety, and disease activity were assessed within 6 weeks after the second vaccine dose. Results Following vaccination, the seropositivity rate and S1/S2 IgG levels were significantly lower among patients with AIIRD versus controls (86% (n=590) vs 100%, p&lt;0.0001 and 132.9±91.7 vs 218.6±82.06 BAU/mL, p&lt;0.0001, respectively). Risk factors for reduced immunogenicity included older age and treatment with glucocorticoids, rituximab, mycophenolate mofetil (MMF), and abatacept. Rituximab was the main cause of a seronegative response (39% seropositivity). There were no postvaccination symptomatic cases of COVID-19 among patients with AIIRD and one mild case in the control group. Major adverse events in patients with AIIRD included death (n=2) several weeks after the second vaccine dose, non-disseminated herpes zoster (n=6), uveitis (n=2), and pericarditis (n=1). Postvaccination disease activity remained stable in the majority of patients. Conclusion mRNA BNTb262 vaccine was immunogenic in the majority of patients with AIIRD, with an acceptable safety profile. Treatment with glucocorticoids, rituximab, MMF, and abatacept was associated with a significantly reduced BNT162b2-induced immunogenicity.
AB0763 IGG4-RELATED CORONARY PERIARTERITIS: SYSTEMATIC LITERATURE REVIEW WITH OUR CASE SERIES
Authors: T. Ito, S. Fukui, T. Kanie, T. Nakai, G. Kidoguchi, H. Ozawa, S. Kawaai, Y. Ikeda, A. Koido, Y. Haji, A. Nomura, H. Tamaki, K. Yamaguchi, M. Okada
Journal: Annals of the Rheumatic Diseases (2021)

Background: Coronary periarteritis is one of the clinical manifestations of IgG4-related disease. It can cause serious conditions such as angina and ruptured aneurysms. Therefore, it is important to recognize the clinical and radiological characteristics, which was little known. Objectives: We report four patients with IgG4-related coronary periarteritis with a systematic literature review. Methods: We identified four patients with IgG4-related coronary periarteritis at the St. Luke’s International Hospital in Tokyo, Japan from 2014 to 2020. A systematic literature review was conducted for English articles on IgG4-related coronary periarteritis cases with a full text or abstract available. We summarized patient demographics, IgG and IgG4 titers, the site and morphological type of coronary lesion, and other organ involvements. Results: Our 4 cases and 38 cases identified by the literature review were assessed. Coronary artery lesions were detected by a coronary CT in all but two cases. Wall thickening was the most common type of the lesion. Moreover, there were 32 (76.1%) patients with other organ involvements. The commonest other lesion was peri-aortitis in 21 (50.0%) patients. In cases with peri-aortitis, IgG and IgG4 titers were significantly higher than those without peri-aortitis (IgG4; 1540 [705.0, 2570.0] vs 246.0 [160.0, 536.3]; p = 0.001, IgG; 3596.5 [2838.3, 4260.0] vs 1779.0 [1288.3, 1992.8]; p =0.040). In addition, 15 (71.4%) patients of them had three or more IgG4 related organ involvements. Conclusion: Coronary CT was a useful imaging modality for the diagnosis of IgG4-related coronary periarteritis, and wall thickening was the most common lesion. Moreover, about half cases coexisted with peri-aortitis. Peri-aortitis and other organ involvements should be screened in those with higher IgG and IgG4. Table 1. Characteristics of our cases and the literature review cases. RCA: right coronary artery, LAD: left anterior descending artery, LCx: left circumflex artery Disclosure of Interests: None declared